StocksMedium•14 October 2026•
1 min read
Lonza Upgrades Midterm Profitability Targets Amid Strategic Pivot to CDMO
Key Facts
1Lonza upgraded its midterm financial ambitions, driven by the maturation of its investment projects.
2The company is narrowing its focus on contract drug manufacturing following the planned sale of its capsules and health ingredients unit.
Lonza Group AG upgraded its midterm financial ambitions, driven by the maturation of its investment projects. The Wall Street Journal reported that the company is narrowing its strategic focus toward contract drug manufacturing following the planned sale of its capsules and health ingredients unit.
The upgrade reflects a strategic pivot toward the core contract development and manufacturing organization (CDMO) business. In equity markets, LZAGY closed at $68.05 on October 13, 2026, having traded between a day high of $68.84 and a day low of $67.81 during that session.